ALKS
insider transactionsAlkermes plc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-51.3K
0 buy · 51.3K sell
Net value · 90d
-$2.0M
$0 in · $2.0M out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
8
0 buy · 51.3K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Director · 10b5-1
$90.2K
2.0K sh · $45.10
Own -7%
-
Sell·S
EVP, CLO, Alkermes, Inc. · 10b5-1
$87.6K
2.0K sh · $43.05
Own -1%
-
Exercise·M
EVP R&D, Chief Medical Officer · 10b5-1
$0
5.0K sh
Own +369%
-
Sell·S
EVP R&D, Chief Medical Officer · 10b5-1
$375.0K
9.0K sh · $41.67
Own -10%
-
Exercise·M
EVP R&D, Chief Medical Officer · 10b5-1
$96.7K
5.0K sh · $19.34
Own +6%
-
Exercise·M
VP, Finance (Interim PAO)
$0
12.8K sh
Own +1282500%
-
Exercise·M
VP, Finance (Interim PAO)
$0
3.4K sh
Own +169600%
-
Sell·S
VP, Finance (Interim PAO)
$687.0K
16.2K sh · $42.36
Own -68%
-
Exercise·M
VP, Finance (Interim PAO)
$248.0K
12.8K sh · $19.34
Own +115%
-
Exercise·M
VP, Finance (Interim PAO)
$67.9K
3.4K sh · $20.03
Own +44%
-
Exercise·M
Director
—
6.1K sh
Own New
-
Other·F
Director
$54.5K
1.5K sh · $36.95
Own -5%
-
Exercise·M
Director
—
6.1K sh
Own +27%
-
Exercise·M
Director
—
6.1K sh
Own New
-
Other·F
Director
$54.5K
1.5K sh · $36.95
Own -4%
-
Exercise·M
Director
—
6.1K sh
Own +20%
-
Exercise·M
Director
—
6.1K sh
Own New
-
Other·F
Director
$54.5K
1.5K sh · $36.95
Own -9%
-
Exercise·M
Director
—
6.1K sh
Own +57%
-
Exercise·M
Director
—
6.1K sh
Own New
-
Other·F
Director
$54.5K
1.5K sh · $36.95
Own -4%
-
Exercise·M
Director
—
6.1K sh
Own +18%
-
Exercise·M
Director
—
6.1K sh
Own New
-
Other·F
Director
$54.5K
1.5K sh · $36.95
Own -7%
-
Exercise·M
Director
—
6.1K sh
Own +45%
-
Exercise·M
Director
—
6.1K sh
Own New
-
Other·F
Director
$54.5K
1.5K sh · $36.95
Own -4%
-
Exercise·M
Director
—
6.1K sh
Own +21%
-
Exercise·M
Director
—
6.1K sh
Own New
-
Other·F
Director
$54.5K
1.5K sh · $36.95
Own -4%
-
Exercise·M
Director
—
6.1K sh
Own +20%
-
Exercise·M
Director
—
6.1K sh
Own New
-
Other·F
Director
$118.5K
3.2K sh · $36.95
Own -3%
-
Exercise·M
Director
—
6.1K sh
Own +6%
-
Grant·A
Director
$0
5.4K sh
Own New
-
Grant·A
Director
$0
11.5K sh
Own New
-
Grant·A
Director
$0
5.4K sh
Own New
-
Grant·A
Director
$0
11.5K sh
Own New
-
Grant·A
Director
$0
5.4K sh
Own New
-
Grant·A
Director
$0
11.5K sh
Own New
-
Grant·A
Director
$0
5.4K sh
Own New
-
Grant·A
Director
$0
11.5K sh
Own New
-
Grant·A
Director
$0
5.4K sh
Own New
-
Grant·A
Director
$0
11.5K sh
Own New
-
Grant·A
Director
$0
5.4K sh
Own New
-
Grant·A
Director
$0
11.5K sh
Own New
-
Grant·A
Director
$0
5.4K sh
Own New
-
Grant·A
Director
$0
11.5K sh
Own New
-
Grant·A
Director
$0
5.4K sh
Own New
-
Grant·A
Director
$0
11.5K sh
Own New
-
Grant·A
Director
$0
5.4K sh
Own New
-
Grant·A
Director
$0
11.5K sh
Own New
-
Grant·A
Director
$0
5.4K sh
Own New
-
Grant·A
Director
$0
11.5K sh
Own New
-
Sell·S
EVP, CLO, Alkermes, Inc. · 10b5-1
$67.5K
2.0K sh · $33.20
Own -1%
-
Exercise·M
EVP R&D, Chief Medical Officer · 10b5-1
$0
5.0K sh
Own +79%
-
Sell·S
EVP R&D, Chief Medical Officer · 10b5-1
$300.6K
9.0K sh · $33.40
Own -10%
-
Exercise·M
EVP R&D, Chief Medical Officer · 10b5-1
$96.7K
5.0K sh · $19.34
Own +6%
-
Exercise·M
Director
—
3.8K sh
Own +375100%
-
Other·F
Director
$30.1K
901 sh · $33.36
Own -6%
-
Exercise·M
Director
—
3.8K sh
Own +35%
-
Sell·S
EVP, CLO, Alkermes, Inc. · 10b5-1
$70.3K
2.0K sh · $34.57
Own -1%
-
Exercise·M
EVP R&D, Chief Medical Officer · 10b5-1
$0
5.0K sh
Own +44%
-
Sell·S
EVP R&D, Chief Medical Officer · 10b5-1
$319.6K
9.0K sh · $35.51
Own -10%
-
Exercise·M
EVP R&D, Chief Medical Officer · 10b5-1
$96.7K
5.0K sh · $19.34
Own +6%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 12, 2026 | Christopher I Wright 10b5-1 | Sell S | 2.0K | $90.2K |
| Jun 4, 2026 | David Joseph Gaffin 10b5-1 | Sell S | 2.0K | $87.6K |
| Jun 1, 2026 | Craig C. Hopkinson 10b5-1 | Exercise M | 5.0K | $0 |
| Jun 1, 2026 | Craig C. Hopkinson 10b5-1 | Sell S | 9.0K | $375.0K |
| Jun 1, 2026 | Craig C. Hopkinson 10b5-1 | Exercise M | 5.0K | $96.7K |
| May 29, 2026 | Samuel Joseph Parisi | Exercise M | 12.8K | $0 |
| May 29, 2026 | Samuel Joseph Parisi | Exercise M | 3.4K | $0 |
| May 29, 2026 | Samuel Joseph Parisi | Sell S | 16.2K | $687.0K |
| May 29, 2026 | Samuel Joseph Parisi | Exercise M | 12.8K | $248.0K |
| May 29, 2026 | Samuel Joseph Parisi | Exercise M | 3.4K | $67.9K |
| May 21, 2026 | Christopher I Wright | Exercise M | 6.1K | — |
| May 21, 2026 | Christopher I Wright | Other F | 1.5K | $54.5K |
| May 21, 2026 | Christopher I Wright | Exercise M | 6.1K | — |
| May 21, 2026 | Frank Anders Wilson | Exercise M | 6.1K | — |
| May 21, 2026 | Frank Anders Wilson | Other F | 1.5K | $54.5K |
| May 21, 2026 | Frank Anders Wilson | Exercise M | 6.1K | — |
| May 21, 2026 | Nancy Lynn Snyderman MD | Exercise M | 6.1K | — |
| May 21, 2026 | Nancy Lynn Snyderman MD | Other F | 1.5K | $54.5K |
| May 21, 2026 | Nancy Lynn Snyderman MD | Exercise M | 6.1K | — |
| May 21, 2026 | Brian P Mckeon | Exercise M | 6.1K | — |
| May 21, 2026 | Brian P Mckeon | Other F | 1.5K | $54.5K |
| May 21, 2026 | Brian P Mckeon | Exercise M | 6.1K | — |
| May 21, 2026 | Nancy Lurker | Exercise M | 6.1K | — |
| May 21, 2026 | Nancy Lurker | Other F | 1.5K | $54.5K |
| May 21, 2026 | Nancy Lurker | Exercise M | 6.1K | — |
| May 21, 2026 | Cato T Laurencin | Exercise M | 6.1K | — |
| May 21, 2026 | Cato T Laurencin | Other F | 1.5K | $54.5K |
| May 21, 2026 | Cato T Laurencin | Exercise M | 6.1K | — |
| May 21, 2026 | Richard Gaynor | Exercise M | 6.1K | — |
| May 21, 2026 | Richard Gaynor | Other F | 1.5K | $54.5K |
| May 21, 2026 | Richard Gaynor | Exercise M | 6.1K | — |
| May 21, 2026 | Shane Cooke | Exercise M | 6.1K | — |
| May 21, 2026 | Shane Cooke | Other F | 3.2K | $118.5K |
| May 21, 2026 | Shane Cooke | Exercise M | 6.1K | — |
| May 20, 2026 | Richard Gaynor | Grant A | 5.4K | $0 |
| May 20, 2026 | Richard Gaynor | Grant A | 11.5K | $0 |
| May 20, 2026 | Shane Cooke | Grant A | 5.4K | $0 |
| May 20, 2026 | Shane Cooke | Grant A | 11.5K | $0 |
| May 20, 2026 | Christopher I Wright | Grant A | 5.4K | $0 |
| May 20, 2026 | Christopher I Wright | Grant A | 11.5K | $0 |
| May 20, 2026 | Frank Anders Wilson | Grant A | 5.4K | $0 |
| May 20, 2026 | Frank Anders Wilson | Grant A | 11.5K | $0 |
| May 20, 2026 | Nancy Lynn Snyderman MD | Grant A | 5.4K | $0 |
| May 20, 2026 | Nancy Lynn Snyderman MD | Grant A | 11.5K | $0 |
| May 20, 2026 | Brian P Mckeon | Grant A | 5.4K | $0 |
| May 20, 2026 | Brian P Mckeon | Grant A | 11.5K | $0 |
| May 20, 2026 | Nancy Lurker | Grant A | 5.4K | $0 |
| May 20, 2026 | Nancy Lurker | Grant A | 11.5K | $0 |
| May 20, 2026 | Cato T Laurencin | Grant A | 5.4K | $0 |
| May 20, 2026 | Cato T Laurencin | Grant A | 11.5K | $0 |
| May 20, 2026 | Richard Gaynor | Grant A | 5.4K | $0 |
| May 20, 2026 | Richard Gaynor | Grant A | 11.5K | $0 |
| May 20, 2026 | Shane Cooke | Grant A | 5.4K | $0 |
| May 20, 2026 | Shane Cooke | Grant A | 11.5K | $0 |
| May 4, 2026 | David Joseph Gaffin 10b5-1 | Sell S | 2.0K | $67.5K |
| May 1, 2026 | Craig C. Hopkinson 10b5-1 | Exercise M | 5.0K | $0 |
| May 1, 2026 | Craig C. Hopkinson 10b5-1 | Sell S | 9.0K | $300.6K |
| May 1, 2026 | Craig C. Hopkinson 10b5-1 | Exercise M | 5.0K | $96.7K |
| Apr 11, 2026 | Nancy Lurker | Exercise M | 3.8K | — |
| Apr 11, 2026 | Nancy Lurker | Other F | 901 | $30.1K |
| Apr 11, 2026 | Nancy Lurker | Exercise M | 3.8K | — |
| Apr 6, 2026 | David Joseph Gaffin 10b5-1 | Sell S | 2.0K | $70.3K |
| Apr 1, 2026 | Craig C. Hopkinson 10b5-1 | Exercise M | 5.0K | $0 |
| Apr 1, 2026 | Craig C. Hopkinson 10b5-1 | Sell S | 9.0K | $319.6K |
| Apr 1, 2026 | Craig C. Hopkinson 10b5-1 | Exercise M | 5.0K | $96.7K |
About ALKS insider trading
This page tracks insider transactions for Alkermes plc. (ALKS) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.